{"status":"success","data":{"title":"Fibrinolysis for Acute Pulmonary Embolism","slug":"pe-fibrinolysis","tags":["alteplase","tpa"],"collection":["Pulmonology","Critical Care"],"content":"<h1 id=\"fibrinolysis-for-acute-pulmonary-embolism-pe-\">Fibrinolysis for Acute Pulmonary Embolism (PE)</h1>\n<p><strong>Massive PE:</strong> Acute PE with at least 1 of the following:</p>\n<ul>\n<li>Sustained hypotension from PE itself (SBP &lt; 90 mmHg for ≥ 15 min, or requiring inotropic support)</li>\n<li>Pulselessness</li>\n<li>Persistent profound bradycardia (HR &lt; 40 bpm with signs/symptoms of shock)</li>\n</ul>\n<p><strong>Submassive PE:</strong> Acute PE without systemic hypotension (SBP ≥ 90 mmHg) but with either RV dysfunction or myocardial necrosis.</p>\n<ul>\n<li><p><em>RV dysfunction:</em> the presence of at least 1 of the following:</p>\n<ul>\n<li>Echo: RV dilation (apical 4-chamber RV diameter divided by LV diameter &gt; 0.9), or RV systolic dysfunction</li>\n<li>CT: RV dilation (4-chamber RV diameter divided by LV diameter &gt; 0.9)</li>\n<li>BNP &gt; 90 pg/mL</li>\n<li>N-terminal pro-BNP &gt; 500 pg/mL</li>\n<li>ECG changes: New complete or incomplete right BBB, anteroseptal ST elevation or depression, or anteroseptal T-wave inversion</li>\n</ul>\n</li>\n<li><p><em>Myocardial necrosis is defined as either of the following</em>:</p>\n<ul>\n<li>Troponin I &gt; 0.4 ng/mL</li>\n<li>Troponin T &gt; 0.1 ng/mL</li>\n</ul>\n</li>\n</ul>\n<p><strong>Low Risk PE</strong>: Acute PE and the absence of clinical markers of adverse prognosis that define massive or submassive PE</p>\n<h2 id=\"fibrinolysis-recommendations\">Fibrinolysis Recommendations</h2>\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td>Reasonable to give:</td>\n<td>Massive acute PE and acceptable risk of bleeding complications.</td>\n</tr>\n<tr class=\"even\">\n<td>Consider giving it:</td>\n<td>Submassive acute PE with clinical evidence of adverse prognosis (new hemodynamic instability, worsening respiratory insufficiency, severe RV dysfunction, or major myocardial necrosis) and low risk of bleeding complications.</td>\n</tr>\n<tr class=\"odd\">\n<td>Not recommended:</td>\n<td><ul>\n<li>Low-risk PE</li>\n<li>Submassive acute PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening</li>\n<li>Undifferentiated cardiac arrest</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n<h2 id=\"fibrinolytic-dosing\">Fibrinolytic dosing</h2>\n<p><strong>Alteplase</strong> 100 mg IV over 2 hours.</p>\n<ul>\n<li>Consider contraindications for Alteplase when deciding to proceed with Rx</li>\n<li>Currently, only FDA approved agents for PE are urokinase, streptokinase, and alteplase. Tenecteplase studies in progress.</li>\n</ul>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=23102885\">Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the &quot;MOPETT&quot; Trial). Am J Cardiol. 2013 Jan 15;111(2):273-7.</a></li>\n<li><a href=\"http://circ.ahajournals.org/content/123/16/1788.full\">Jaff MR et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary HTN. Circulation. 2011;123(16):1788-830.</a></li>\n</ul>\n"}}